Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: An intent-to-treat analysis

Journal of Clinical Oncology

Volumn 21, Issue 22, 2003, Pages 4151-4156

  Abrey, Lauren E ^a   Moskowitz, Craig H ^a   Mason, Warren P ^a   Crump, Michael ^a   Stewart, Douglas ^a   Forsyth, Peter ^a   Paleologos, Nina ^a   Correa, Denise D ^a   Anderson, Nicole D ^a   Caron, Dawn ^a   Zelenetz, Andrew ^a   Nimer, Stephen D ^a   DeAngelis, Lisa M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN; METHOTREXATE; ANTINEOPLASTIC AGENT; BEAM REGIMEN;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD BRAIN BARRIER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEUROIMAGING; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; ADULT; AGED; AUTOTRANSPLANTATION; CENTRAL NERVOUS SYSTEM TUMOR; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; MIDDLE AGED; MORTALITY; NONHODGKIN LYMPHOMA; PATHOLOGY; PROSPECTIVE STUDY; REMISSION; SAFETY; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CYTARABINE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; REMISSION INDUCTION; SAFETY; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0642316783     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.024     Document Type: Article

References (25)

1. Deangelis LM: Current management of primary central nervous system lymphoma. Oncology 9:63-76, 1995
2. Fisher R, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
3. Coltman AC Jr, Dahlberg S, Jones ES, et al: CHOP is curative in thirty percent of patients with large cell lymphoma: A twelve year Southwest Oncology Group follow up. Skarin AT (ed): Update on Treatment for Diffuse Large Cell Lymphoma. New York, NY, Park Row, 1986, pp 71-77
4. Abrey LE, Yahalom J, DeAngelis LM: Treatment for primary central nervous system lymphoma (PCNSL): The next step. J Clin Oncol 18:3144-3150, 2000
5. DeAngelis LM, Seiferheld W, Schold SC, et al: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4643-4648, 2002
6. Glass J, Gruber ML, Cher L, et al: Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long term outcome. J Neurosurg 81:188-195, 1994
7. Abrey LE, Yahalom J, DeAngelis LM: Long term survival in primary central nervous system lymphoma (PCNSL). J Clin Oncol 16:859-863, 1998
8. Abrey LE, Yahalom J, DeAngelis LM: Relapse and late neurotoxicity in primary central nervous system lymphoma. Neurology 48:A18, 1997 (abstr 18)
9. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
10. Soussain C, Suzan F, Hoang-Xuan K, et al: Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19:742-749, 2001
11. Kewalramani T, Moskowitz CH: Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: Who benefits? Curr Oncol Rep 3:271-278, 2001
12. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high dose therapy in poor-risk non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol-A Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 18:3025-3030, 2000
13. Doolittle ND, Miner ME, Hall WA, et al: Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88:637-647, 2000
14. Edelstein M, Vietti T, Valeriote F: The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate. Cancer Res 35:1555-1558, 1975
15. Cadman E, Eiferman F: Mechanisms of synergistic cell killing when methotrexate precedes cytosine arabinoside. J Clin Invest 64:788-797, 1979
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Martelli M, Gherlinzoni F, De Renzo A, et al: Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial. J Clin Oncol 21:1255-1262, 2003
18. Santini G, Coser P, Congiu AM, et al: VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: A study by the non-Hodgkin's Lymphoma Co-operative Study Group. Haematologica 85:160-166, 2000
19. Batchelor T, Carson K, O'Neill A, et al: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol 21:1044-1049, 2003
20. DeAngelis LM, Seiferheld W, Schold SC, et al: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4615-4617, 2002
21. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al: Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst 93:4-5, 2001
22. Herrlinger U, Schabet M, Brugger W, et al: German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 51:247-252, 2002
23. Wiebe VJ, Smith BR, DeGregorio MW, et al: Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol 13:241-270, 1992
24. Cheng T, Forsyth P, Chaudhry A, et al: Lymphoma: High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 31:679-685, 2003
25. Cairncross JG, Swinnen L, Bayer R, et al: Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. J Neurooncol 2:114-119, 2000